...
首页> 外文期刊>Expert opinion on therapeutic targets >Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment.
【24h】

Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment.

机译:半胱氨酸白三烯受体CysLT1作为变应性鼻炎治疗的新型治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Cysteinyl leukotrienes (cys-LTs) play an important role in allergic rhinitis because CysLT(1) receptor antagonists relieve the symptoms of allergic rhinitis. Objective: I overview the clinical pharmacology of CysLT(1) receptor antagonists and their potential role in patients with allergic rhinitis. Methods: I review the evidence regarding the release of cys-LTs and localization of CysLT(1) receptor on nasal mucosa, and evaluate the clinical efficacy of CysLT(1) receptor antagonist in allergic rhinitis. Results/conclusion: Immunohistochemical studies show that in allergic rhinitis, the major target of CysLT(1) receptor antagonists are the vascular bed and infiltrated leukocytes such as mast cells, eosinophils and macrophages. CysLT(1) receptor antagonists provide a new opportunity for simultaneous management of allergic diseases of the upper and lower respiratory tract.
机译:背景:半胱氨酰白三烯(cys-LTs)在变应性鼻炎中起重要作用,因为CysLT(1)受体拮抗剂可缓解变应性鼻炎的症状。目的:我概述了CysLT(1)受体拮抗剂的临床药理及其在变应性鼻炎患者中的潜在作用。方法:我回顾了有关cys-LTs释放和CysLT(1)受体在鼻粘膜上定位的证据,并评估了CysLT(1)受体拮抗剂在变应性鼻炎中的临床疗效。结果/结论:免疫组织化学研究表明,在变应性鼻炎中,CysLT(1)受体拮抗剂的主要靶标是血管床和浸润的白细胞,例如肥大细胞,嗜酸性粒细胞和巨噬细胞。 CysLT(1)受体拮抗剂为同时管理上呼吸道和下呼吸道的过敏性疾病提供了新的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号